Chemomab Reports Top-Line Results from CM-101 Phase 2a Liver

—CM-101 Met Primary Endpoint of Safety and Tolerability and Showed Positive Activity Across Multiple Liver Fibrosis Biomarkers and Physiologic Assessments—
TEL AVIV, Israel, Jan. 3, 2023... | January 3, 2023

Related Keywords

New York , United States , Jerusalem , Israel General , Israel , Dale Pfost , Irina Koffler , Barbara Lindheim , Sheila Sherlock , Massimo Pinzani , Rifaat Safadi , Digestive Health , University College London , Division Of Liver Diseases , Lifesci Advisors , Mount Sinai School Of Medicine , Institute For Liver , Chemomab Therapeutics Ltd , Nasdaq , Hadassah University Hospital , Strategic Communications , Prnewswire Chemomab Therapeutics Ltd , Primary Endpoint , Physiologic Assessments , Chief Executive Officer , Sheila Sherlock Chair , Visiting Scholar , Liver Diseases , Mount Sinai School , New York City , Principal Investigator , Private Securities Litigation Reform , Liver Fibrosis Biomarker , Sci Advisors , Public Relations , Chemomab Therapeutics Ltd Stock Exchange , News , Information , Press Release , Pet , Primary , Ndpoint , F , Safety , End , Tolerability , Howed , Positive , Activity , Cross , Multiple , Liver , Ibrosis , Biomarkers , Hysiologic Cmmb Us16385c1045 ,